GU Cancers 2025 | EV and pembrolizumab as first-line therapy for urothelial carcinoma
Dora Niedersüß-Beke
• 14 Feb 2025
Dora Niedersüß-Beke, MD, MBA, Klinik Ottakring, Vienna, Austria, describes on the evolving role of enfortumab vedotin with pembrolizumab in the frontline setting for urothelial carcinoma. Due to Austria’s fast reimbursement and early implementation of the novel therapies, it has become new standard of care for metastatic and locally advanced urethral cancer. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
